The patient perspective

PREFER looks at how and when it is best to perform and include patient-preference in decision making during the drug life cycle. We include patient stakeholders at every level of the project. The end-result will be recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies.

Irina Cleemput, KCE, public co-lead for recommendations

Patient preferences through a public eye

For patient preferences to be useful in decision-making processes, they have to be measured in a valid and reliable way. However, to be successful, the methods recommended by PREFER also have to be user-friendly and affordable.

Apart from risk-benefit balance of treatments, HTA has many more additional considerations when preparing for a reimbursement decision. Here, Irina Cleemput, public co-lead for recommendations, shares the HTA perspective and her view on how it is represented in PREFER.

Read interview

Vikas Soekhai, PhD Student

Challenges and opportunities in patient preference assessment

Patient preferences are taking on an increasingly important role in the lifecycle of medical products. The methods to assess preferences are many, and PREFER will contribute knowledge on which methods are best suited at different points. As part of his PhD project, Vikas Soekhai will help identify methods and simulate the impact the choice of method may have on preference study results. 

Vikas Soekhai's PhD will contribute to PREFER knowledge on the challenges and opportunities involved in assessments of patient preferences throughout the whole lifecycle of drugs and medical devices.

Read interview

Karin Schölin Bywall, PhD Student, Uppsala University

PREFER PhD project on rheumatoid arthritis

In March this year, Karin Schölin Bywall started her PhD studies at Uppsala University. Her project is part of PREFER. It will look at how rheumatoid arthritis patient preferences can add value when regulators make decisions on drug development.

According to Karin Schölin Bywall, the PREFER project offers the chance to work with PhD students from other universities. PREFER also allows her to develop research questions with senior researchers from universities and the pharmaceutical industry. This collaboration also ensures stakeholder perspectives in her PhD project.

Find out more

Finding out what patients prefer

Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when and where patients want, can, and should be involved in drug development.

We are looking forward to sharing our findings with you!

Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader

Mats G. Hansson, co-ordinator & Conny Berlin, project leader, PREFER